Executive Summary: Standards of Medical Care
in Diabetesd2014
CURRENT CRITERIA FOR THE
DIAGNOSIS OF DIABETES
c A1C $6.5%. The test should be
performed in a laboratory using a
method that is NGSP certified and
standardized to the DCCT assay. Or
c Fasting plasma glucose (FPG) $126
mg/dL (7.0 mmol/L). Fasting is
defined as no caloric intake for at
least 8 h. Or
c Two-hour plasma glucose $200 mg/
dL (11.1 mmol/L) during an oral
glucose tolerance test (OGTT). The
test should be performed as
described by the World Health
Organization, using a glucose load
containing the equivalent of 75 g
anhydrous glucose dissolved in water.
Or
c In a patient with classic symptoms of
hyperglycemia or hyperglycemic
crisis, a random plasma glucose$200
mg/dL (11.1 mmol/L).
c In the absence of unequivocal
hyperglycemia, result should be
confirmed by repeat testing.
TESTING FOR DIABETES IN
ASYMPTOMATIC PATIENTS
c Testing to detect type 2 diabetes and
prediabetes in asymptomatic people
should be considered in adults of any
age who are overweight or obese
(BMI $25 kg/m2) and who have one
or more additional risk factors for
diabetes. In those without these risk
factors, testing should begin at age 45
years. B
c If tests are normal, repeat testing at
least at 3-year intervals is reasonable.
E
c To test for diabetes or prediabetes, the
A1C, FPG, or 2-h 75-g OGTT are
appropriate. B
c In those identified with prediabetes,
identify and, if appropriate, treat
other cardiovascular disease (CVD)
risk factors. B
SCREENING FOR TYPE 2 DIABETES
IN CHILDREN
c Testing to detect type 2 diabetes and
prediabetes should be considered in
children and adolescents who are
overweight and who have two or
more additional risk factors for
diabetes. E
SCREENING FOR TYPE 1 DIABETES
c Inform type 1 diabetic patients of the
opportunity to have their relatives
screened for type 1 diabetes risk in
the setting of a clinical research
study. E
DETECTION AND DIAGNOSIS OF
GESTATIONAL DIABETES MELLITUS
c Screen for undiagnosed type 2
diabetes at the first prenatal visit in
those with risk factors, using standard
diagnostic criteria. B
c Screen for gestational diabetes
mellitus (GDM) at 24–28 weeks of
gestation in pregnant women not
previously known to have diabetes. A
c Screen women with GDM for
persistent diabetes at 6–12 weeks
postpartum, using the OGTT and
nonpregnancy diagnostic criteria. E
c Women with a history of GDM should
have lifelong screening for the
development of diabetes or
prediabetes at least every 3 years. B
c Women with a history of GDM found
to have prediabetes should receive
lifestyle interventions or metformin
to prevent diabetes. A
c Further research is needed to
establish a uniform approach to
diagnosing GDM. E
PREVENTION/DELAY OF TYPE 2
DIABETES
c Patients with impaired glucose
tolerance (IGT) A, impaired fasting
glucose (IFG) E, or an A1C 5.7–6.4% E
should be referred to an effective
ongoing support program targeting
weight loss of 7% of body weight and
increasing physical activity to at least
150 min/week of moderate activity
such as walking.
c Follow-up counseling appears to be
important for success. B
c Based on the cost-effectiveness of
diabetes prevention, such programs
should be covered by third-party
payers. B
c Metformin therapy for prevention of
type 2 diabetes may be considered in
those with IGTA, IFG E, or an A1C 5.7–
6.4% E, especially for those with BMI
.35 kg/m2, aged ,60 years, and
women with prior GDM. A
c At least annual monitoring for the
development of diabetes in those
with prediabetes is suggested. E
c Screening for and treatment of
modifiable risk factors for CVD is
suggested. B
GLUCOSE MONITORING
c Patients on multiple-dose insulin
(MDI) or insulin pump therapy should
do self-monitoring of blood glucose
(SMBG) prior to meals and snacks,
occasionally postprandially, at
bedtime, prior to exercise, when they
suspect low blood glucose, after
treating low blood glucose until they
are normoglycemic, and prior to
critical tasks such as driving. B
c When prescribed as part of a broader
educational context, SMBG results
may be helpful to guide treatment
decisions and/or patient self-
management for patients using less
DOI: 10.2337/dc14-S005
© 2014 by the American Diabetes Association. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
Diabetes Care Volume 37, Supplement 1, January 2014 S5
EX
EC
U
TIV
E
SU
M
M
A
R
Y
guide.medlive.cn
frequent insulin injections or
noninsulin therapies. E
c When prescribing SMBG, ensure that
patients receive ongoing instruction
and regular evaluation of SMBG
technique and SMBG results, as well
as their ability to use SMBG data to
adjust therapy. E
c When used properly, continuous
glucose monitoring (CGM) in
conjunction with intensive insulin
regimens is a useful tool to lower A1C
in selected adults (aged $25 years)
with type 1 diabetes. A
c Although the evidence for A1C
lowering is less strong in children,
teens, and younger adults, CGM may
be helpful in these groups. Success
correlates with adherence to ongoing
use of the device. C
c CGM may be a supplemental tool to
SMBG in those with hypoglycemia
unawareness and/or frequent
hypoglycemic episodes. E
A1C
c Perform the A1C test at least two
times a year in patients who are
meeting treatment goals (and who
have stable glycemic control). E
c Perform the A1C test quarterly in
patients whose therapy has changed or
who are not meeting glycemic goals. E
c Use of point-of-care (POC) testing for
A1C provides the opportunity for
more timely treatment changes. E
GLYCEMIC GOALS IN ADULTS
c Lowering A1C to below or around 7%
has been shown to reduce
microvascular complications of
diabetes and, if implemented soon
after the diagnosis of diabetes, is
associated with long-term reduction
in macrovascular disease.
Therefore, a reasonable A1C goal for
many nonpregnant adults is ,7%. B
c Providers might reasonably suggest
more stringent A1C goals (such as
,6.5%) for selected individual
patients, if this can be achieved
without significant hypoglycemia or
other adverse effects of treatment.
Appropriate patients might include
those with short duration of diabetes,
long life expectancy, and no
significant CVD. C
c Less stringent A1C goals (such as
,8%) may be appropriate for
patients with a history of severe
hypoglycemia, limited life
expectancy, advanced microvascular
or macrovascular complications, and
extensive comorbid conditions and in
those with long-standing diabetes in
whom the general goal is difficult to
attain despite diabetes self-
management education (DSME),
appropriate glucose monitoring, and
effective doses of multiple glucose-
lowering agents including insulin. B
PHARMACOLOGICAL AND OVERALL
APPROACHES TO TREATMENT
Insulin Therapy for Type 1 Diabetes
c Most people with type 1 diabetes
should be treated with MDI injections
(three to four injections per day of
basal and prandial insulin) or
continuous subcutaneous insulin
infusion (CSII). A
c Most people with type 1 diabetes
should be educated in how to match
prandial insulin dose to carbohydrate
intake, premeal blood glucose, and
anticipated activity. E
c Most people with type 1 diabetes
should use insulin analogs to reduce
hypoglycemia risk. A
Screening
c Consider screening those with type 1
diabetes for other autoimmune
diseases (thyroid, vitamin B12
deficiency, celiac) as appropriate. B
Pharmacological Therapy for
Hyperglycemia in Type 2 Diabetes
c Metformin, if not contraindicated
and if tolerated, is the preferred
initial pharmacological agent for type
2 diabetes. A
c In newly diagnosed type 2 diabetic
patients with markedly symptomatic
and/or elevated blood glucose levels
or A1C, consider insulin therapy, with
or without additional agents, from
the outset. E
c If noninsulin monotherapy at
maximum tolerated dose does not
achieve or maintain the A1C target
over 3 months, add a second oral
agent, a glucagon-like peptide 1 (GLP-
1) receptor agonist, or insulin. A
c A patient-centered approach should
be used to guide choice of
pharmacological agents.
Considerations include efficacy, cost,
potential side effects, effects on
weight, comorbidities, hypoglycemia
risk, and patient preferences. E
c Due to the progressive nature of type
2 diabetes, insulin therapy is
eventually indicated for many
patients with type 2 diabetes. B
MEDICAL NUTRITION THERAPY
General Recommendations
c Nutrition therapy is recommended
for all people with type 1 and type 2
diabetes as an effective component
of the overall treatment plan. A
c Individuals who have prediabetes or
diabetes should receive
individualized medical nutrition
therapy (MNT) as needed to achieve
treatment goals, preferably provided
by a registered dietitian familiar with
the components of diabetes MNT. A
c Because diabetes nutrition therapy
can result in cost savings B and
improved outcomes such as reduction
in A1C A, nutrition therapy should be
adequately reimbursed by insurance
and other payers. E
Energy Balance, Overweight, and
Obesity
c For overweight or obese adults with
type 2 diabetes or at risk for diabetes,
reducing energy intake while
maintaining a healthful eating
pattern is recommended to promote
weight loss. A
c Modest weight loss may provide
clinical benefits (improved glycemia,
blood pressure, and/or lipids) in some
individuals with diabetes, especially
those early in the disease process. To
achieve modest weight loss, intensive
lifestyle interventions (counseling
about nutrition therapy, physical
activity, and behavior change) with
ongoing support are recommended. A
Eating Patterns and Macronutrient
Distribution
c Evidence suggests that there is not an
ideal percentage of calories from
carbohydrate, protein, and fat for all
people with diabetes B; therefore,
macronutrient distribution should be
based on individualized assessment
of current eating patterns, preferences,
and metabolic goals. E
c A variety of eating patterns
(combinations of different foods or
food groups) are acceptable for the
management of diabetes. Personal
S6 Executive Summary Diabetes Care Volume 37, Supplement 1, January 2014
guide.medlive.cn
preference (e.g., tradition, culture,
religion, health beliefs and goals,
economics) and metabolic goals
should be considered when
recommending one eating pattern
over another. E
Carbohydrate Amount and Quality
c Monitoring carbohydrate intake,
whether by carbohydrate counting or
experience-based estimation,
remains a key strategy in achieving
glycemic control. B
c For good health, carbohydrate intake
from vegetables, fruits, whole grains,
legumes, and dairy products should
be advised over intake from other
carbohydrate sources, especially
those that contain added fats, sugars,
or sodium. B
c Substituting low-glycemic load foods
for higher-glycemic load foods may
modestly improve glycemic control. C
c People with diabetes should consume
at least the amount of fiber andwhole
grains recommended for the general
public. C
c While substituting sucrose-
containing foods for isocaloric
amounts of other carbohydrates may
have similar blood glucose effects,
consumption should be minimized to
avoid displacing nutrient-dense food
choices. A
c People with diabetes and those at risk
for diabetes should limit or avoid
intake of sugar-sweetened beverages
(from any caloric sweetener including
high-fructose corn syrup and sucrose)
to reduce risk for weight gain and
worsening of cardiometabolic risk
profile. B
Dietary Fat Quantity and Quality
c Evidence is inconclusive for an ideal
amount of total fat intake for people
with diabetes; therefore, goals should
be individualized. C Fat quality
appears to be far more important
than quantity. B
c In people with type 2 diabetes, a
Mediterranean-style, MUFA-rich eating
pattern may benefit glycemic control
and CVD risk factors and can therefore
be recommended as an effective
alternative to a lower-fat, higher-
carbohydrate eating pattern. B
c As recommended for the general
public, an increase in foods
containing long-chain n-3 fatty acids
(EPA and DHA) (from fatty fish) and
n-3 linolenic acid (ALA) is recommended
for individuals with diabetes because
of their beneficial effects on
lipoproteins, prevention of heart
disease, and associations with positive
health outcomes in observational
studies. B
c The amount of dietary saturated fat,
cholesterol, and trans fat
recommended for people with
diabetes is the same as that
recommended for the general
population. C
Supplements for Diabetes
Management
c There is no clear evidence of benefit
from vitamin or mineral
supplementation in people with
diabetes who do not have underlying
deficiencies. C
c Routine supplementation with
antioxidants, such as vitamins E and
C and carotene, is not advised
because of lack of evidence of efficacy
and concern related to long-term
safety. A
c Evidence does not support
recommending n-3 (EPA and DHA)
supplements for people with diabetes
for the prevention or treatment of
cardiovascular events. A
c There is insufficient evidence to
support the routine use of
micronutrients such as chromium,
magnesium, and vitamin D to
improve glycemic control in people
with diabetes. C
c There is insufficient evidence to
support the use of cinnamon or other
herbs/supplements for the treatment
of diabetes. C
c It is reasonable for individualized meal
planning to include optimization of food
choices to meet recommended daily
allowance/dietary reference intake for
all micronutrients. E
Alcohol
c If adults with diabetes choose to drink
alcohol, they should be advised to do
so in moderation (one drink per day or
less for adult women and two drinks
per day or less for adult men). E
c Alcohol consumption may place
people with diabetes at increased risk
for delayed hypoglycemia, especially
if taking insulin or insulin
secretagogues. Education and
awareness regarding the recognition
and management of delayed
hypoglycemia is warranted. C
Sodium
c The recommendation for the general
population to reduce sodium to
,2,300 mg/day is also appropriate
for people with diabetes. B
c For individuals with both diabetes
and hypertension, further reduction
in sodium intake should be
individualized. B
Primary Prevention of Type 2 Diabetes
c Among individuals at high risk for
developing type 2 diabetes,
structured programs that emphasize
lifestyle changes that include
moderate weight loss (7% of body
weight) and regular physical activity
(150 min/week), with dietary
strategies including reduced calories
and reduced intake of dietary fat, can
reduce the risk for developing
diabetes and are therefore
recommended. A
c Individuals at high risk for type 2
diabetes should be encouraged to
achieve the U.S. Department of
Agriculture (USDA) recommendation
for dietary fiber (14 g fiber/1,000 kcal)
and foods containing whole grains
(one-half of grain intake). B
DIABETES SELF-MANAGEMENT
EDUCATION AND SUPPORT
c People with diabetes should receive
DSME and diabetes self-management
support (DSMS) according to National
Standards for Diabetes Self-
Management Education and Support
when their diabetes is diagnosed and
as needed thereafter. B
c Effective self-management and
quality of life are the key outcomes of
DSME and DSMS and should be
measured and monitored as part of
care. C
c DSME and DSMS should address
psychosocial issues, since emotional
well-being is associated with positive
diabetes outcomes. C
c DSME and DSMS programs are
appropriate venues for people with
prediabetes to receive education and
support to develop and maintain
behaviors that can prevent or delay
the onset of diabetes. C
care.diabetesjournals.org Executive Summary S7
guide.medlive.cn
c Because DSME and DSMS can result
in cost-savings and improved
outcomes B, DSME and DSMS should
be adequately reimbursed by third-
party payers. E
PHYSICAL ACTIVITY
c As is the case for all children, children
with diabetes or prediabetes should
be encouraged to engage in at least
60 min of physical activity each day. B
c Adults with diabetes should be
advised to perform at least 150 min/
week of moderate-intensity aerobic
physical activity (50–70% of
maximum heart rate), spread over
at least 3 days/week with no more
than 2 consecutive days without
exercise. A
c In the absence of contraindications,
adults with type 2 diabetes should be
encouraged to perform resistance
training at least twice per week. A
PSYCHOSOCIAL ASSESSMENT AND
CARE
c It is reasonable to include assessment
of the patient’s psychological and
social situation as an ongoing part
of the medical management of
diabetes. B
c Psychosocial screening and follow-up
may include, but are not limited to,
attitudes about the illness,
expectations for medical
management and outcomes, affect/
mood, general and diabetes-related
quality of life, resources (financial,
social, and emotional), and
psychiatric history. E
c Routinely screen for psychosocial
problems such as depression and
diabetes-related distress, anxiety,
eating disorders, and cognitive
impairment. B
HYPOGLYCEMIA
c Individuals at risk for hypoglycemia
should be asked about symptomatic
and asymptomatic hypoglycemia at
each encounter. C
c Glucose (15–20 g) is the preferred
treatment for the conscious
individual with hypoglycemia,
although any form of carbohydrate
that contains glucose may be used.
After 15 min of treatment, if SMBG
shows continued hypoglycemia, the
treatment should be repeated. Once
SMBG returns to normal, the
individual should consume a meal or
snack to prevent recurrence of
hypoglycemia. E
c Glucagon should be prescribed for all
individuals at significant risk of severe
hypoglycemia, and caregivers or
family members of these individuals
should be instructed on its
administration. Glucagon
administration is not limited to health
care professionals. E
c Hypoglycemia unawareness or one or
more episodes of severe hypoglycemia
should trigger re-evaluation of the
treatment regimen. E
c Insulin-treated patients with
hypoglycemia unawareness or an
episode of severe hypoglycemia
should be advised to raise their
glycemic targets to strictly avoid
further hypoglycemia for at least
several weeks, to partially reverse
hypoglycemia unawareness and
reduce risk of future episodes. A
c Ongoing assessment of cognitive
function is suggested with increased
vigilance for hypoglycemia by the
clinician, patient, and caregivers if
low cognition and/or declining
cognition is found. B
BARIATRIC SURGERY
c Bariatric surgery may be
considered for adults with BMI
.35 kg/m2 and type 2 diabetes,
especially if diabetes or associated
comorbidities are difficult to control
with lifestyle and pharmacological
therapy. B
c Patients with type 2 diabetes who
have undergone bariatric surgery
need lifelong lifestyle support and
medical monitoring. B
c Although small trials have shown
glycemic benefit of bariatric surgery
in patients with type 2 diabetes and
BMI 30–35 kg/m2, there is currently
insufficient evidence to generally
recommend surgery in patients with
BMI,35 kg/m2 outside of a research
protocol. E
c The long-term benefits, cost-
effectiveness, and risks of bariatric
surgery in individuals with type 2
diabetes should be studied in well-
designed controlled trials with
optimal medical and lifestyle therapy
as the comparator. E
IMMUNIZATION
c Annually provide an influenza vaccine
to all diabetic patients $6 months of
age. C
c Administer pneumococcal
polysaccharide vaccine to all diabetic
patients $2 years of age. A one-time
revaccination is recommended for
individuals .65 years of age who
have been immunized .5 years ago.
Other indications for repeat
vaccination include nephrotic
syndrome, chronic renal disease, and
other immunocompromised states,
such as after transplantation. C
c Administer hepatitis B vaccination
to unvaccinated adults with diabetes
who are aged 19–59 years. C
c Consider administering hepatitis B
vaccination to unvaccinated adults
with diabetes who are aged
$60 years. C
HYPERTENSION/BLOOD
本文档为【2014+ADA+糖尿病医学诊疗标准(执行摘要)】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑,
图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
该文档来自用户分享,如有侵权行为请发邮件ishare@vip.sina.com联系网站客服,我们会及时删除。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。
本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。
网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。